FindTrial
Sign In

Blood Loss and Cost-Effective?of Oral vs intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Clinical Trial

Blood Loss and Cost-Effective?of Oral vs intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015265
Enrollment
Unknown
Registered
2018-03-19
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip Arthroplasty

Interventions

A:Oral Tranexamic Acid
B:intravenous Tranexamic Acid

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with THA

Exclusion criteria

Exclusion criteria: Infection, anemia, revision surgery, anaphylactic acid allergies

Design outcomes

Primary

MeasureTime frame
blood loss;transfusion requirements;TXA cost;—

Countries

China

Contacts

Public ContactBin Shen

West China Hospital, Sichuan University

wuyuangang23@163.com+86 18980601390

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026